{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:43:24Z","timestamp":1791935004361,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Ketoconazole is extensively used as an index inhibitor of cytochrome P450-3A (CYP3A) activity in vitro and in vivo, but the mechanism of ketoconazole inhibition of CYP3A still is not clearly established.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Inhibition of metabolite formation by ketoconazole (seven concentrations from 0.01 to 1.0 \u00b5m) was studied in human liver microsomes (n = 4) at six to seven substrate concentrations for triazolam, midazolam, and testosterone, and at two substrate concentrations for nifedipine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key findings<\/jats:title><jats:p>Analysis of multiple data points per liver sample based on a mixed competitive\u2013noncompetitive model yielded mean inhibition constant Ki values in the range of 0.011 to 0.045 \u00b5m. Ketoconazole IC50 increased at higher substrate concentrations, thereby excluding pure noncompetitive inhibition. For triazolam, testosterone, and midazolam \u03b1-hydroxylation, mean values of \u03b1 (indicating the \u2018mix\u2019 of competitive and noncompetitive inhibition) ranged from 2.1 to 6.3. However, inhibition of midazolam 4-hydroxylation was consistent with a competitive process. Determination of Ki and \u03b1 based on the relation between 50% inhibitory concentration values and substrate concentration yielded similar values. Pre-incubation of ketoconazole with microsomes before addition of substrate did not enhance inhibition, whereas inhibition by troleandomycin was significantly enhanced by pre-incubation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ketoconazole inhibition of triazolam \u03b1- and 4-hydroxylation, midazolam \u03b1-hydroxylation, testosterone 6\u03b2-hydroxylation, and nifedipine oxidation appeared to be a mixed competitive\u2013noncompetitive process, with the noncompetitive component being dominant but not exclusive. Quantitative estimates of Ki were in the low nanomolar range for all four substrates.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.2042-7158.2010.01202.x","type":"journal-article","created":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T17:59:21Z","timestamp":1295027961000},"page":"214-221","source":"Crossref","is-referenced-by-count":114,"title":["Mechanism of cytochrome P450-3A inhibition by ketoconazole"],"prefix":"10.1093","volume":"63","author":[{"given":"David J","family":"Greenblatt","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Venkatakrishnan","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals Inc. , Cambridge, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su X","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerold S","family":"Harmatz","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J","family":"Parent","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H","family":"Court","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L","family":"von Moltke","sequence":"additional","affiliation":[{"name":"Genzyme Corp. , Cambridge, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,2,1]]},"reference":[{"key":"2024103013295080000_cit1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"2024103013295080000_cit2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1039\/9781847558428-00354","article-title":"The CYP3 family","volume-title":"Cytochrome P450: Role in the Metabolism and Toxicology of Drugs and Other Xenobiotics","author":"Greenblatt","year":"2008"},{"key":"2024103013295080000_cit3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/978-1-4419-0840-7_24","article-title":"Clinical studies of drug-drug interactions: design and interpretation","volume-title":"Enzyme and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges","author":"Greenblatt","year":"2010"},{"key":"2024103013295080000_cit4","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3109\/00498254.2010.506224","article-title":"Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro","volume":"40","author":"Greenblatt","year":"2010","journal-title":"Xenobiotica"},{"key":"2024103013295080000_cit5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.abb.2004.09.010","article-title":"Modelling atypical CYP3A4 kinetics: principles and pragmatism","volume":"433","author":"Houston","year":"2005","journal-title":"Arch Biochem Biophys"},{"key":"2024103013295080000_cit6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1365-2125.1999.00073.x","article-title":"CYP3A4 drug interactions: correlation of 10 in vitro probe substrates","volume":"48","author":"Kenworthy","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"2024103013295080000_cit7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000139107","article-title":"Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes","volume":"47","author":"von Moltke","year":"1993","journal-title":"Pharmacology"},{"key":"2024103013295080000_cit8","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/dmd.31.7.938","article-title":"In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5","volume":"31","author":"Patki","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"2024103013295080000_cit9","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1124\/dmd.31.9.1108","article-title":"Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine","volume":"31","author":"Galetin","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"2024103013295080000_cit10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0022-3565(25)12284-2","article-title":"Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole","volume":"276","author":"von Moltke","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103013295080000_cit11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0022-3565(24)35332-7","article-title":"Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms","volume":"292","author":"Perloff","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103013295080000_cit12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/j.1552-4604.1996.tb04251.x","article-title":"Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents","volume":"36","author":"von Moltke","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"2024103013295080000_cit13","volume-title":"Enzyme Kinetics","author":"Segel","year":"1975"},{"key":"2024103013295080000_cit14","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1177\/00912700122012724","article-title":"Human drug metabolism and the cytochromes P450: application and relevance of in vitro models","volume":"41","author":"Venkatakrishnan","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"2024103013295080000_cit15","first-page":"75","article-title":"In vitro approaches to anticipating clinical drug interactions","volume-title":"Drug-Drug Interactions in Pharmaceutical Development","author":"Volak","year":"2008"},{"key":"2024103013295080000_cit16","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1124\/dmd.107.017095","article-title":"Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination","volume":"35","author":"Brown","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"2024103013295080000_cit17","first-page":"70","article-title":"Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site","volume":"29","author":"Schrag","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"2024103013295080000_cit18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0090-9556(25)07487-2","article-title":"Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450","volume":"24","author":"Ghosal","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"2024103013295080000_cit19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(94)90543-6","article-title":"Regioselective biotransformation of midazolam by members of the human Cytochrome P450 3A (CYP3A) subfamily","volume":"47","author":"Gorski","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"2024103013295080000_cit20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/jpet.104.082826","article-title":"CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions","volume":"314","author":"Galetin","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103013295080000_cit21","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1021\/bi992765t","article-title":"Elucidation of distinct ligand binding sites for cytochrome P450 3A4","volume":"39","author":"Hosea","year":"2000","journal-title":"Biochemistry"},{"key":"2024103013295080000_cit22","first-page":"368","article-title":"Substrate inhibition kinetics for cytochrome P450-catalyzed reactions","volume":"29","author":"Lin","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"2024103013295080000_cit23","first-page":"1644","article-title":"Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism","volume":"29","author":"Kenworthy","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"2024103013295080000_cit24","doi-asserted-by":"crossref","first-page":"6636","DOI":"10.1073\/pnas.95.12.6636","article-title":"Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics","volume":"95","author":"Harlow","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024103013295080000_cit25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1021\/bi962359z","article-title":"Cooperativity in oxidations catalyzed by cytochrome P450 3A4","volume":"36","author":"Ueng","year":"1997","journal-title":"Biochemistry"},{"key":"2024103013295080000_cit26","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"2024103013295080000_cit27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/978-1-4419-0840-7_19","article-title":"Inactivation of human Cytochrome P450 enzymes and drug-drug interactions","volume-title":"Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges","author":"Obach","year":"2010"},{"key":"2024103013295080000_cit28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.31.3.289","article-title":"Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine","volume":"31","author":"Bertelsen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"2024103013295080000_cit29","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/138920005774330639","article-title":"Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity","volume":"6","author":"Fontana","year":"2005","journal-title":"Curr Drug Metab"},{"key":"2024103013295080000_cit30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s002280000125","article-title":"Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole","volume":"56","author":"von Moltke","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"2024103013295080000_cit31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1211\/002235702739","article-title":"Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir","volume":"55","author":"Weemhoff","year":"2003","journal-title":"J Pharm Pharmacol"},{"key":"2024103013295080000_cit32","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1124\/dmd.104.002931","article-title":"Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro","volume":"33","author":"Perloff","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"2024103013295080000_cit33","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2133\/dmpk.24.500","article-title":"Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition","volume":"24","author":"Sekiguchi","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"2024103013295080000_cit34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.1994.tb04317.x","article-title":"Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine","volume":"38","author":"von Moltke","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"2024103013295080000_cit35","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/j.1552-4604.1994.tb04735.x","article-title":"In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction","volume":"34","author":"von Moltke","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"2024103013295080000_cit36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/138920008784746364","article-title":"Heterotropic cooperativity in oxidation mediated by Cytochrome P450","volume":"9","author":"Niwa","year":"2008","journal-title":"Curr Drug Metab"},{"key":"2024103013295080000_cit37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","article-title":"The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions","volume":"316","author":"Obach","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2024103013295080000_cit38","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.clpt.2005.09.004","article-title":"In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach","volume":"78","author":"Obach","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"2024103013295080000_cit39","doi-asserted-by":"crossref","first-page":"810","DOI":"10.2174\/138920007782798135","article-title":"Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis","volume":"8","author":"Ragueneau-Majlessi","year":"2007","journal-title":"Curr Drug Metab"},{"key":"2024103013295080000_cit40","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.2042-7158.2010.01202.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/63\/2\/214\/60235946\/j.2042-7158.2010.01202.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/63\/2\/214\/60235946\/j.2042-7158.2010.01202.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T20:15:38Z","timestamp":1740860138000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/63\/2\/214\/6135476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,1]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,2,1]]},"published-print":{"date-parts":[[2011,2,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.2042-7158.2010.01202.x","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,2]]},"published":{"date-parts":[[2011,2,1]]}}}